Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.38 |
| ▸ | CNR1 | P21554 | 14/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936329 | 0.84 | ALDH2 (0.38) | ALDH2ALDH3A1 | |
| SCHEMBL11336865 | 0.78 | CNR1 (0.39) | CNR2CNR1 | |
| SCHEMBL2935573 | 0.75 | MEN1 (0.43) | ALDH2ALDH3A1 | |
| SCHEMBL2934963 | 0.75 | TYR (0.41) | CNR2CNR1ALDH2ALDH3A1 | |
| SCHEMBL126588 | 0.74 | CNR1 (0.49) | CNR2CNR1 | |
| SCHEMBL11222329 | 0.73 | CNR1 (0.51) | CNR2CNR1 | |
| SCHEMBL5693667 | 0.73 | CNR1 (0.51) | CNR2CNR1 | |
| SCHEMBL8861296 | 0.73 | CNR1 (0.51) | CNR2CNR1 | |
| SCHEMBL9335370 | 0.73 | CNR1 (0.51) | CNR2CNR1 | |
| SCHEMBL2934063 | 0.72 | ALDH2 (0.43) | CNR2ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2229169-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009089880-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | RCC1, RB1, RCC2 | CNR2 623/4885CNR1 261/4885NR1I2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.